Press Releases Year None20232022202120202019201820172015 December 1, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 9, 2023 ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences November 6, 2023 ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates November 3, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) November 2, 2023 ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting October 21, 2023 Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile October 17, 2023 ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023 October 6, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) September 20, 2023 ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference September 1, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 27